Gufic Biosciences Limited (GUFICBIO.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹418.45 (+2.72%) as of
Key statistics
- Market cap
- 41.96B
- P/E (TTM)
- 57.17
- EPS (TTM)
- 7.32
- Dividend yield
- 0.02%
- 52-week range
- 268.00 – 467.80
- Beta
- -0.03
- Revenue (TTM)
- 9.81B
- Profit margin
- 7.49%
- Volume
- 33.74k
About Gufic Biosciences Limited
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Mumbai, India
- Employees
- 1,607
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.